Literature DB >> 20945381

Oncoprotein Cot1 represses kinase suppressors of Ras1/2 and 1,25-dihydroxyvitamin D3-induced differentiation of human acute myeloid leukemia cells.

Xuening Wang1, George P Studzinski.   

Abstract

Metabolites and derivatives of vitamin D are well-known inducers of monocytic differentiation, but the mechanistic basis for their action is not fully elucidated. Here we show that the product of protooncogene Cot1 represses the monocytic phenotype in human acute myeloid leukemia (AML) cells induced to differentiate by 1,25-dihydroxyvitamin D(3) (1,25D), even though the expression of cellular Cot1 increases early in the process of 1,25D-induced differentiation. Interestingly, the expression of the two members of the Kinase Suppressor of Ras (KSR) family of molecular scaffolds, known to be positive regulators of Ras signaling and of 1,25D-induced differentiation, increases in parallel with Cot1 in 1,25D-treated cells. However, KSR1/2 are negatively regulated by Cot1, as determined by transfection of siCot1, and confirmed by a reverse effect of ectopic expression of Cot1. The effect of Cot1 in AML cells appears to be cell-type specific, as previous reports in other cell types found KSR-2 to be a negative regulator of Cot1, a reverse relationship. Also in contrast to findings in other cells, in AML cells Cot1 exerts negative control on the MAP kinase pathways, since siCot1 increases the levels of activated Raf1, p90RSK, JNK1, c-jun, and p38, though not of MEK/ERK. These findings have implications for therapy of AML, since in AML cells active MAPKs hasten cell differentiation, and specific pharmacological inhibitors of Cot1 kinase activity have recently became available, thus making Cot1 a "druggable" target.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20945381      PMCID: PMC3440184          DOI: 10.1002/jcp.22449

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  51 in total

1.  The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genes.

Authors:  Rachit Bakshi; Mohammad Q Hassan; Jitesh Pratap; Jane B Lian; Martin A Montecino; Andre J van Wijnen; Janet L Stein; Anthony N Imbalzano; Gary S Stein
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

Review 2.  Vitamin D and differentiation in cancer.

Authors:  Elzbieta Gocek; George P Studzinski
Journal:  Crit Rev Clin Lab Sci       Date:  2009       Impact factor: 6.250

3.  Establishment and characterization of a human histiocytic lymphoma cell line (U-937).

Authors:  C Sundström; K Nilsson
Journal:  Int J Cancer       Date:  1976-05-15       Impact factor: 7.396

4.  Expression of MAP3 kinase COT1 is up-regulated by 1,25-dihydroxyvitamin D3 in parallel with activated c-jun during differentiation of human myeloid leukemia cells.

Authors:  Xuening Wang; George P Studzinski
Journal:  J Steroid Biochem Mol Biol       Date:  2010-03-19       Impact factor: 4.292

5.  Isoforms of p38MAPK gamma and delta contribute to differentiation of human AML cells induced by 1,25-dihydroxyvitamin D₃.

Authors:  Jing Zhang; Jonathan S Harrison; George P Studzinski
Journal:  Exp Cell Res       Date:  2010-09-08       Impact factor: 3.905

6.  Synergistic antileukemic activity of carnosic acid-rich rosemary extract and the 19-nor Gemini vitamin D analogue in a mouse model of systemic acute myeloid leukemia.

Authors:  Ayelet Shabtay; Hagar Sharabani; Zeev Barvish; Michael Kafka; Doron Amichay; Joseph Levy; Yoav Sharoni; Milan R Uskokovic; George P Studzinski; Michael Danilenko
Journal:  Oncology       Date:  2008-10-14       Impact factor: 2.935

7.  Silibinin can induce differentiation as well as enhance vitamin D3-induced differentiation of human AML cells ex vivo and regulates the levels of differentiation-related transcription factors.

Authors:  Jing Zhang; Jonathan S Harrison; Milan Uskokovic; Michael Danilenko; George P Studzinski
Journal:  Hematol Oncol       Date:  2010-09       Impact factor: 5.271

Review 8.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

Authors:  John Koreth; Richard Schlenk; Kenneth J Kopecky; Sumihisa Honda; Jorge Sierra; Benjamin J Djulbegovic; Martha Wadleigh; Daniel J DeAngelo; Richard M Stone; Hisashi Sakamaki; Frederick R Appelbaum; Hartmut Döhner; Joseph H Antin; Robert J Soiffer; Corey Cutler
Journal:  JAMA       Date:  2009-06-10       Impact factor: 56.272

9.  Inhibition of tumor progression locus 2 protein kinase suppresses receptor activator of nuclear factor-kappaB ligand-induced osteoclastogenesis through down-regulation of the c-Fos and nuclear factor of activated T cells c1 genes.

Authors:  Kazuya Hirata; Hirofumi Taki; Kouichiro Shinoda; Hiroyuki Hounoki; Tatsuro Miyahara; Kazuyuki Tobe; Hirofumi Ogawa; Hisashi Mori; Eiji Sugiyama
Journal:  Biol Pharm Bull       Date:  2010       Impact factor: 2.233

10.  c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D.

Authors:  Xiangwen Chen-Deutsch; Edward Garay; Jing Zhang; Jonathan S Harrison; George P Studzinski
Journal:  Leuk Res       Date:  2009-03-31       Impact factor: 3.156

View more
  5 in total

1.  Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D(3).

Authors:  Xuening Wang; Elzbieta Gocek; Victoria Novik; Jonathan S Harrison; Michael Danilenko; George P Studzinski
Journal:  Cell Cycle       Date:  2010-11-15       Impact factor: 4.534

2.  Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis.

Authors:  Veronica Caraffini; Olivia Geiger; Angelika Rosenberger; Stefan Hatzl; Bianca Perfler; Johannes L Berg; Clarice Lim; Herbert Strobl; Karl Kashofer; Silvia Schauer; Christine Beham-Schmid; Gerald Hoefler; Klaus Geissler; Franz Quehenberger; Walter Kolch; Dimitris Athineos; Karen Blyth; Albert Wölfler; Heinz Sill; Armin Zebisch
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

3.  IKBKE-driven TPL2 and MEK1 phosphorylations sustain constitutive ERK1/2 activation in tumor cells.

Authors:  Serkan Ismail Göktuna
Journal:  EXCLI J       Date:  2022-02-18       Impact factor: 4.068

Review 4.  The Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia Therapy.

Authors:  Elzbieta Gocek; George P Studzinski
Journal:  J Clin Med       Date:  2015-03-25       Impact factor: 4.241

Review 5.  RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis.

Authors:  Armin Zebisch; Veronica Caraffini; Heinz Sill
Journal:  Int J Mol Sci       Date:  2019-11-16       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.